Minerva Neurosciences (NERV) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Minerva Neurosciences is running a Phase 3 study (NCT07565428) to test Roluperidone in adults with schizophrenia who have ongoing negative symptoms but stable positive symptoms. The study aims to show that Roluperidone can ease these hard to treat symptoms over 12 weeks and then compare relapse rates over another 40 weeks, which could support a new, focused treatment option.
The main treatment is Roluperidone (MIN-101), an oral drug taken once a day. It is being tested as a stand alone option and is also compared against standard oral antipsychotics like risperidone, aripiprazole, and olanzapine, with placebo used in the early phase to clarify the drug’s effect.
The study is interventional and randomized, so patients are assigned by chance to different treatment paths. It is double blind with four parties masked, meaning patients, doctors, and assessors do not know who is on which treatment, which helps reduce bias and keeps the focus on real symptom changes.
The trial started recruiting on 21 April 2026 and is now listed as recruiting, signaling active site ramp up. The latest update to the record was filed on 13 May 2026, showing that the sponsor is maintaining fresh information, though primary and final completion dates are not yet posted.
For investors in Minerva Neurosciences (NERV), this new large Phase 3 program is a key value driver and a major risk point. A credible path to data could lift sentiment and support the stock, while delays or weak results would likely pressure shares and benefit larger rivals that sell current antipsychotics.
The schizophrenia drug space is crowded, but few drugs target negative symptoms directly, so success here could give NERV a niche edge. The update that the trial is actively recruiting may draw fresh speculative interest, yet until clear timelines and early signals emerge, trading is likely to stay news driven and volatile.
The Roluperidone Phase 3 study is currently ongoing and recently updated, with more details available on the ClinicalTrials portal.
To learn more about NERV’s potential, visit the Minerva Neurosciences drug pipeline page.